Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695274 | 0.93 | KDM4E (0.43) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL1695270 | 0.88 | CDK1 (0.47) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL1550687 | 0.87 | CDK1 (0.62) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL5074576 | 0.86 | CDK1 (0.49) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL5073627 | 0.84 | HRH3 (0.44) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL5074614 | 0.84 | TMEM97 (0.50) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL1550842 | 0.81 | KDM4E (0.44) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL1550998 | 0.80 | KDM4E (0.58) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL1695306 | 0.80 | CDK1 (0.44) | CDK1CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL4745970 | 0.79 | TMEM97 (0.60) | CDK1CHRM2CHRM4CHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2023043953-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-4126066-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4121063-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2021195469-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021188390-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2585113-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012163814-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | INSTITUT CURIE (FR) | 2012-12-06 | — | — | WO | disclosed |
| WO-2011161075-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA THERAPEUTICS (FR) | 2011-12-29 | — | — | WO | disclosed |
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | CDK1 2596/4885CHRM2 3199/4885CHRM4 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.